Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET HIGHLANDS RANCH Colorado, March 31, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive…

Pioneer in Treating Dentofacial Abnormalities and / or Mild-to-Moderate Obstructive Sleep Apnea Ranks Among Top 10 Most Innovative Medical Device Companies of the Year HIGHLANDS RANCH Colorado, March 08, 2022 HIGHLANDS RANCH, Colo., March 08, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing…

The Vivos Method’s Proprietary Combination of Multidisciplinary Protocols and Oral Appliances Featured on New Corporate Website HIGHLANDS RANCH Colorado, March 03, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild…

Vivos Therapeutics to Participate in Upcoming Investor Conferences HIGHLANDS RANCH Colorado, March 02, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and…

Vivos Medical Advisory Board to Expound on Clinical Data Set of Improved Patient Outcomes at One of the World’s Largest Sleep Conferences HIGHLANDS RANCH Colorado, February 24, 2022 HIGHLANDS RANCH, Colo., Feb. 24, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic…

Vivos’ Continuous Clinical Improvement Program Yields Promising Data in AHI Score Reductions for Patients with Obstructive Sleep Apnea HIGHLANDS RANCH Colorado, January 27, 2022 Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep…

Vivos Also Announces Improved Pricing Agreement With SleepImage Dentists and Patients Report Exceptional User Experience with SleepImage Home Sleep Test HIGHLANDS RANCH Colorado, January 19, 2022 Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate…

mmRNA is the first and only appliance of its kind covered by Medicare Part of the Vivos System treatment, the mmRNA appliance represents a highly effective, nonsurgical, noninvasive, and nonpharmaceutical alternative for patients suffering from OSA and snoring. HIGHLANDS RANCH Colorado, December 14, 2021 Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology…

Vivos management to present at 11:45 am Eastern Time on November 17, 2021 HIGHLANDS RANCH Colorado, December 9, 2021 Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, today…

Third Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening of Live Training Facility, Expansion of Marketing Programs, Additional FDA Approval and Positive Study Results Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH Colorado, November 15, 2021 Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a…